ModifiedAmbetter NevadaPolicy CP.MP.142

Urinary Incontinence Devices and Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.142 alerts

Get alerted when Policy CP.MP.142 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria and coding guidance for sacral neuromodulation (SNM/SNS) and FDA‑approved urethral bulking agent (UBA) injections for treatment of lower urinary tract dysfunction and stress urinary incontinence for members/enrollees.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedAmbetter NevadaPolicy CP.MP.142

Urinary Incontinence Devices and Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.142 alerts

Get alerted when Policy CP.MP.142 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyUrinary Incontinence Devices and Treatments

Policy CodePolicy CP.MP.142

Change TypeClarified device approvalrevised symptom durationclarified test response threshold

Effective Date

Last ReviewSep 19, 2025

Next Review Date

Key ActionObtain prior authorization to confirm criteria for medical necessity before proceeding with SNM trial, permanent implant, or FDA‑approved urethral bulking agent injection.

SourceLink

POLICY UPDATE CHANGES

Added language that SNM devices must be United States FDA approved in Criteria I and II.

Changed symptom duration requirement for urinary retention from 12 months to at least 6 months.

Updated verbiage in Criteria II.B. to state 'at least' a 50% reduction in symptoms for proceeding to permanent SNM.

>=6 monthsminimum symptom duration for SNM candidacy

>=50%minimum symptom reduction on percutaneous test

3-7 daystypical SNM test period

23literature & regulatory refs

Coverage Criteria — SNM and Urethral Bulking Agents

Initial SNM trial (I)

Covered when ALL of the following are met:

SNM trial criteria

Failure of conservative measures
- For urgency/frequency or incontinence: documented trial of bladder training, pelvic floor physical therapy with biofeedback, and appropriate pharmacologic treatment.
- For non-obstructive urinary retention: documented trial of intermittent self-catheterization unless not well tolerated, and appropriate pharmacologic treatment.

Device requirement: Trial must be performed with a United States Food and Drug Administration (FDA) approved device.

Permanent SNM implantation (II)

Covered when ALL of the following are met:

Permanent SNM placement: All criteria in Initial SNM trial (section I) are met; and a percutaneous stimulation test provided at least a 50% reduction in incontinence, retention, or urgency/frequency symptoms prior to permanent device implantation.>=50%

Device requirement: Permanent implantation must use a United States Food and Drug Administration (FDA) approved device.

Urethral bulking agent injections (III)

Covered when ALL of the following are met:

Urethral bulking agents: Diagnosis of persistent or recurrent stress urinary incontinence due to intrinsic sphincter deficiency, post-bladder support surgery, or post-traumatic/surgical injury; failure of conservative management such as pelvic floor therapy, biofeedback, electrical stimulation, and pharmacotherapies; and the member/enrollee is unable to tolerate surgery or does not wish to have surgery.

Examples of FDA-approved agents: FDA-approved periurethral bulking products include (examples): carbon-coated zirconium oxide beads in water-based gel (Durasphere EXP), crosslinked polydimethylsiloxane (Macroplastique), calcium hydroxylapatite in gel (Coaptite), and polyacrylamide hydrogel (Bulkamid).

Insufficient evidence / Not supported (IV)

Unsupported UBA uses: Injection of urethral bulking agents that are autologous fat, non‑FDA approved procedures, or any other circumstances not specified in the covered indications is considered unsupported due to insufficient evidence in the published peer‑reviewed literature.

Sacral neuromodulation (SNM) is indicated only for non‑obstructive urinary retention or overactive bladder and is not intended for obstructive retention. The policy explicitly states that symptoms must be not related to a neurologic condition, and that candidates must have documented failure of specified conservative therapies (e.g., bladder training, pelvic floor physical therapy with biofeedback, pharmacologic treatment for urgency/frequency or incontinence; intermittent self‑catheterization and pharmacologic treatment for non‑obstructive urinary retention unless not tolerated).

When applying the SNM criteria operationally, confirm the diagnosis is non‑obstructive and document prior conservative care and why neurologic causes do not explain the presenting symptoms. Failure to document these elements may result in denial of coverage for trial or permanent implantation.

Injection of urethral bulking agents (UBA) that involve autologous fat or procedures that are not U.S. FDA‑approved are considered unsupported due to insufficient evidence in the published peer‑reviewed literature. The policy lists UBA as medically necessary only when an FDA‑approved agent is used and specified clinical criteria are met.

Providers proposing novel or non‑FDA UBA techniques (including autologous biologic injections) should be aware that these uses are considered investigational/unsupported by this policy and are not eligible for coverage under the stated medical necessity criteria.

Coverage determinations under this clinical policy are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and applicable state and federal requirements. Where state Medicaid provisions or other legal/regulatory requirements conflict with this policy, those requirements take precedence.

Operationally, providers must follow plan‑level prior authorization procedures and verify member benefits and contract language; this clinical policy is a guide to medical necessity but does not guarantee payment or override contract provisions.

Coding Guidance

UBA CPTCPTCovered

51715

Endoscopic injection of implant material into the submucosal tissue of the urethra and/or bladder neck.

SNM CPTCPTCovered

64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

HCPCS — test leads and bulking agentsHCPCSCovered

A4290	Sacral nerve stimulation test lead, each.
L8603	Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies.
L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies.

Implantable neurostimulator HCPCSHCPCSCovered

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only.
L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8684	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

1–10 of 11

1/2

Percutaneous stimulation test response — key metric

Percutaneous stimulation test responseAt least 50% reduction in incontinence, retention, or urgency/frequency symptoms required before permanent SNM implantation

Purpose of testTemporary percutaneous stimulation is used to determine clinical response prior to permanent device placement

Timing noted in policyTest response is evaluated before proceeding to permanent implant as part of Criteria II.B

Symptom duration for candidacy — key metric

Minimum symptom durationSymptoms (incontinence, urgency/frequency, or urinary retention) present for at least 6 months

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for sacral neuromodulation (SNM) and urethral bulking agent (UBA) procedures. Providers must obtain approval before scheduling trial or permanent SNM procedures and before UBA injections so medical necessity can be confirmed.

Prior authorization required before percutaneous SNM test leads, trial stimulation, permanent implantation, and UBA injections.
Failure to obtain prior authorization may result in claim denial or payment delay.

Note

Coverage Decision Dependencies

Coverage determinations are governed by the enrollee's benefit contract. This clinical policy provides medical necessity guidance but does not replace or override the specific terms, conditions, exclusions, and limitations of the member's coverage document.

Coverage subject to plan-level terms, exclusions, and limitations (e.g., Evidence of Coverage, Certificate of Coverage).
For Medicare members, applicable NCDs, LCDs, and Medicare Coverage Articles take precedence; review CMS resources prior to applying this policy.

Definitions and Device/Agent Descriptions

Sacral neuromodulation (SNM / SNS) — concise definition and typical use

DefinitionMinimally invasive electrical stimulation of sacral nerves (usually S3) delivered via an implantable system to treat lower urinary tract dysfunction

Typical targetS3 (and less frequently S4) sacral nerve via transforaminal lead placement

Example systemInterStim system (implantable lead connected to a stimulation device)

Urethral bulking agents (UBA) — definition and purpose

DefinitionInjectable periurethral substances placed to increase tissue bulk and reduce stress urinary incontinence

Primary purposeOption for persistent or recurrent stress urinary incontinence in patients who decline or cannot tolerate surgery

Background

Sacral neuromodulation (SNM) delivers minimally invasive electrical stimulation to the sacral nerves (commonly the S3 root) via an implanted lead and pulse generator to modulate bladder and pelvic floor function. It is used to treat non‑obstructive urinary retention and overactive bladder symptoms.

SNM therapy is typically evaluated with a temporary percutaneous stimulation test prior to permanent implantation; the usual test stimulation evaluation period is approximately 3–7 days, after which response is assessed.

Clinical candidacy requires symptoms that have persisted and caused significant disability for at least 6 months and documentation of prior conservative management. A positive response on the percutaneous test (defined elsewhere in the policy as at least 50% symptom reduction) is required before proceeding with permanent implantation.

Policy Summary

PayerAmbetter Nevada

PolicyUrinary Incontinence Devices and Treatments

Policy CodePolicy CP.MP.142

Change TypeClarified device approvalrevised symptom durationclarified test response threshold

Effective Date

Last ReviewSep 19, 2025

Next Review Date

Key ActionObtain prior authorization to confirm criteria for medical necessity before proceeding with SNM trial, permanent implant, or FDA‑approved urethral bulking agent injection.

SourceLink

On This Page

Applies to non-obstructive urinary retention and overactive bladder candidacy for SNM trial (Criteria I.B)

Rationale reflected in policy changesDuration was revised from 12 months to at least 6 months in the annual review

For Medicaid members, state Medicaid coverage provisions supersede this clinical policy where conflicts exist.

Billing Rule

Coding Documentation

Claims must include appropriate CPT and HCPCS codes and sufficient clinical documentation to support medical necessity. Codes provided in the clinical policy are informational and inclusion/exclusion does not guarantee coverage; verify coding with current professional coding guidance before claim submission.

Common CPT codes: 51715, 64561, 64581, 64585, 64590, 64595.
Common HCPCS/LT codes: A4290, L8603, L8606, L8679–L8689.
Ensure documentation ties codes to the clinical indication and the services performed (e.g., trial lead placement vs permanent implant).

Documentation Required

Documentation and Policy Alignment

Providers must follow this clinical policy and any applicable NCDs/LCDs/state rules; maintain complete records to substantiate medical necessity for SNM and UBA procedures.

Retain documentation of diagnoses, symptom duration, prior conservative therapies, test stimulation results, and informed consent.
If federal/state Medicare or Medicaid rules apply, reference and document conformity with those determinations when submitting claims.
Clinical notes should clearly reference the specific policy criteria met for approval (see policy sections I–IV).

Step Therapy

Conservative Therapy Requirement

Conservative therapy must be documented and failed prior to proceeding with SNM or UBA therapy. Providers should record the type, duration, and response to conservative treatments.

For urgency/frequency or incontinence: documentation of bladder training, pelvic floor physical therapy with biofeedback, and pharmacologic treatment.
For non-obstructive urinary retention: documentation of intermittent self-catheterization (if tolerated) and pharmacologic treatment.
For UBA: documentation of failure of pelvic floor therapy, biofeedback, electrical stimulation, and pharmacotherapies prior to injection.

Denial Risk

Triggers for Denial

Triggers that commonly lead to denial include missing or inadequate documentation of conservative therapy failure and lack of objective improvement on test stimulation prior to permanent SNM implantation.

Absence of documentation showing failure of required conservative measures.
For SNM permanent implantation: no documentation that a percutaneous stimulation test produced ≥50% reduction in symptoms.
Incomplete or missing coding/clinical notes tying the procedure to the member's diagnosis and policy criteria.

Note

Provider Operational Notes

Providers should perform any additional operational steps required by the Health Plan (e.g., prior authorization portals, pre-service review forms) and ensure adherence to the plan's administrative policies.

Follow Health Plan-level operational procedures for authorization submission and appeals.
Be aware that this clinical policy may be updated; check plan resources for the effective policy date and any administrative notices.

FDA‑approved examples (policy lists)Durasphere EXP, Macroplastique, Coaptite, Bulkamid

Sacral neuromodulation — international guidance and indications

International guidanceNICE guidance references sacral nerve stimulation for urge incontinence and urgency‑frequency (IPG64)

Clinical roleDevice‑based therapy referenced in international best practice and professional society statements for urge incontinence and urgency‑frequency

Testing before implantationSNM is typically trialed (3–7 days) to evaluate response prior to permanent implantation

Urethral bulking agents — materials and regulatory references

Injectable materials listedCarbon‑coated zirconium oxide beads in gel (Durasphere), crosslinked polydimethylsiloxane (Macroplastique), calcium hydroxylapatite in gel (Coaptite), polyacrylamide hydrogel (Bulkamid)

Regulatory referencesFDA PMA/PMA summaries cited for Durasphere (P980053), Macroplastique (P040050), Coaptite, and Bulkamid (P170023)

Clinical notePolicy states lower long‑term efficacy vs surgical options and that repeat injections are common